Revenue Grows, But the Timing Mismatch Is Real

On the surface, revenue growth of 12.8% looks healthy. But Gem's consolidated P&L swung to a loss of ₹7.9 Cr—a sharp reversal from prior expectations of "significantly better than FY26." The culprit is not commercial failure; it's a timing mismatch between capex depreciation and new product ramp. The Dahej facility (₹265 Cr capitalized, ~98% of ₹270 Cr total) is now running full depreciation of ₹9.1 Cr per quarter, while the three new verticals meant to justify that capex—Safranal, cooling agents, phenol—remain in approval and trial phases. Standalone, the core Gem business stayed profitable at ₹7.3 Cr. The Krystal subsidiary drags consolidated results by ₹15.2 Cr.

Gross margin compressed to 16.7% from prior baselines, hit by clove cost inflation from the Madagascar port closure (30-day shutdown in March–April 2026). Material flow normalized by May, but elevated pricing persists. The combination of higher raw material costs, standby capacity expense at Dahej, and a product mix weighted toward early-stage, lower-margin output explains why EBITDA margin collapsed to 3.3%—roughly one-fifth of the 16–18% target management has guided for FY28.

FY27 guidance formally withdrawn. The prior call (FY26 earnings) promised FY27 would be "significantly better than FY26, closer to FY25 performance." This quarter, management explicitly deferred FY27 guidance, calling it a "ramp-up year only." No margin outlook, no revenue target—just a timeline of when new products hit commercialization (Safranal Q2+, cooling agents Q3+, phenol Q3 trial, Q4 meaningful contribution). This is a substantial reset.

Dahej capex substantially complete. ₹265 Cr of the ₹270 Cr facility is now capitalized and live. The capex phase is over; the utilization phase has begun. But because production is at pilot/approval stage, the facility is a margin drag until volume scales. No major capex guidance provided, meaning depreciation remains structurally baked into P&L until revenue does the heavy lifting.

New customer wins validate strategy but carry execution risk. Cooling agents secured approval from two of the world's largest companies in that category—tangible competitive validation. Safranal approvals in place across oral care, confectionery, FMCG. But management refused to disclose order sizes or customer names, stating "will clarify as quarters pass." The evasion suggests either orders are small or uncertain, and it reduces near-term visibility.

Gem's stock is priced at ₹175.55, down 25.6% from its all-time high of ₹235.95 but up 31.89% off its 52-week low of ₹133.1. It trades below its 20-day and 50-day moving averages (₹180.94 and ₹184.16, respectively) but above its 200-day average (₹173.8), a pattern consistent with a stock losing momentum but not yet in downtrend. RSI of 43.9 indicates neutral positioning with no extreme oversold or overbought condition. Institutional ownership has shifted: FII holdings fell sharply to 0.75% from 1.06% a quarter ago, suggesting foreign investors are trimming exposure. DII holding steady at 4.81%. Promoter ownership rose to 57.45% from 57.01%, indicating the family is holding firm. The FII exit is noteworthy—it mirrors the market's skepticism on near-term execution and valuation after the loss. The stock's 25% drawdown from ATH is not extreme, but it reflects the street's recognition that the path to FY28 targets runs through a loss-making FY27. The fact that FII is exiting suggests the market is assigning a material probability to execution delays or a slower-than-guided ramp. Until Q3 visibility on new product contribution lands, institutional demand is likely to remain muted.